Abstract
Peptides have emerged as important therapeutics that are being rigorously tested in angiogenesis-dependent diseases due to their low toxicity and high specificity. Since the discovery of endogenous proteins and protein fragments that inhibit microvessel formation (thrombospondin, endostatin) several peptides have shown promise in pre-clinical and clinical studies for cancer. Peptides have been derived from thrombospondin, collagens, chemokines, coagulation cascade proteins, growth factors, and other classes of proteins and target different receptors. Here we survey recent developments for anti-angiogenic peptides with length not exceeding 50 amino acid residues that have shown activity in pre-clinical models of cancer or have been tested in clinical trials; some of the peptides have been modified and optimized, e.g., through L-to-D and non-natural amino acid substitutions. We highlight technological advances in peptide discovery and optimization including computational and bioinformatics tools and novel experimental techniques.
Keywords: Angiogenesis, animal model, computational biology, inhibitor, in vitro model, peptidomimetics, tumor vasculature, tumor, angiogenesis-dependent diseases, microvessel formation, cancer, anti-angiogenic peptides, non-natural amino acid substitutions, anti-cancer agents
Current Pharmaceutical Biotechnology
Title: Anti-Angiogenic Peptides for Cancer Therapeutics
Volume: 12 Issue: 8
Author(s): Elena V. Rosca, Jacob E. Koskimaki, Corban G. Rivera, Niranjan B. Pandey, Amir P. Tamiz and Aleksander S. Popel
Affiliation:
Keywords: Angiogenesis, animal model, computational biology, inhibitor, in vitro model, peptidomimetics, tumor vasculature, tumor, angiogenesis-dependent diseases, microvessel formation, cancer, anti-angiogenic peptides, non-natural amino acid substitutions, anti-cancer agents
Abstract: Peptides have emerged as important therapeutics that are being rigorously tested in angiogenesis-dependent diseases due to their low toxicity and high specificity. Since the discovery of endogenous proteins and protein fragments that inhibit microvessel formation (thrombospondin, endostatin) several peptides have shown promise in pre-clinical and clinical studies for cancer. Peptides have been derived from thrombospondin, collagens, chemokines, coagulation cascade proteins, growth factors, and other classes of proteins and target different receptors. Here we survey recent developments for anti-angiogenic peptides with length not exceeding 50 amino acid residues that have shown activity in pre-clinical models of cancer or have been tested in clinical trials; some of the peptides have been modified and optimized, e.g., through L-to-D and non-natural amino acid substitutions. We highlight technological advances in peptide discovery and optimization including computational and bioinformatics tools and novel experimental techniques.
Export Options
About this article
Cite this article as:
V. Rosca Elena, E. Koskimaki Jacob, G. Rivera Corban, B. Pandey Niranjan, P. Tamiz Amir and S. Popel Aleksander, Anti-Angiogenic Peptides for Cancer Therapeutics, Current Pharmaceutical Biotechnology 2011; 12 (8) . https://dx.doi.org/10.2174/138920111796117300
DOI https://dx.doi.org/10.2174/138920111796117300 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Tumor Angiogenesis: A Target for Renal Cell Carcinoma Therapy. Current Perspectives and Novel Strategies
Recent Patents on Biomarkers Targeting the Nucleus: An Overview of Auger-Electron Radionuclide Therapy
Current Drug Discovery Technologies The Application of Single Nucleotide Polymorphism Microarrays in Cancer Research
Current Genomics The Proteolytic Activation of Angiogenic and Lymphangiogenic Growth Factors in Cancer – Its Potential Relevance for Therapeutics and Diagnostics
Current Medicinal Chemistry Exploring the Synthesis and Anticancer Potential of L-Tyrosine-Platinum(II) Hybrid Molecules
Medicinal Chemistry Open Architecture PCR-Based Methods for Differential Gene Expression Analysis
Current Pharmaceutical Analysis Emerging Concepts in the Analysis of Mitochondrial Genome Instability
Current Genomics Anticancer Drugs Discovery and Development from Marine Organisms
Current Topics in Medicinal Chemistry Cyclooxygenase-2 (COX-2) Mediates Arsenite Inhibition of UVB-Induced Cellular Apoptosis in Mouse Epidermal Cl41 Cells
Current Cancer Drug Targets Erdafitinib as a Novel and Advanced Treatment Strategy of Metastatic Urothelial Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Past, Present and Future Therapeutics for Cerebellar Ataxias
Current Neuropharmacology Should we Target Allergen Protease Activity to Decrease the Burden of Allergic Airway Inflammation?
Inflammation & Allergy - Drug Targets (Discontinued) Garlic-Derived Allyl Sulfides in Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Modified Polysaccharides as Versatile Materials in Controlled Delivery of Antidegenerative Agents
Current Pharmaceutical Design PI3K/Akt Signalling Pathway Specific Inhibitors: A Novel Strategy to Sensitize Cancer Cells to Anti-Cancer Drugs
Current Pharmaceutical Design Fanconi Anemia Proteins, DNA Interstrand Crosslink Repair Pathways, and Cancer Therapy
Current Cancer Drug Targets Exploring the Role of Gene Therapy for Neurological Disorders
Current Gene Therapy Strategies to Increase the Oral Bioavailability of Nucleoside Analogs
Current Medicinal Chemistry The ERK 1 and 2 Pathway in the Nervous System: From Basic Aspects to Possible Clinical Applications in Pain and Visceral Dysfunction
Current Neuropharmacology Surface Binding of Toxins and Heavy Metals by Probiotics
Mini-Reviews in Medicinal Chemistry